OncoSec Medical Incorporated (NASDAQ:ONCS)‘s stock had its “buy” rating reissued by research analysts at Maxim Group in a research note issued to investors on Tuesday. They currently have a $5.00 price objective on the biotechnology company’s stock. Maxim Group’s target price indicates a potential upside of 400.00% from the company’s current price.

ONCS has been the subject of a number of other reports. ValuEngine downgraded shares of OncoSec Medical from a “sell” rating to a “strong sell” rating in a research note on Monday, October 2nd. Dawson James reissued a “buy” rating and issued a $5.00 price target on shares of OncoSec Medical in a research note on Thursday, July 6th. Noble Financial reissued a “buy” rating on shares of OncoSec Medical in a research note on Wednesday, June 14th. Finally, HC Wainwright set a $6.00 price target on shares of OncoSec Medical and gave the stock a “buy” rating in a research note on Monday, June 12th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. OncoSec Medical presently has an average rating of “Buy” and a consensus price target of $5.33.

Shares of OncoSec Medical (ONCS) traded down 0.1300% during mid-day trading on Tuesday, reaching $0.9987. The company’s stock had a trading volume of 154,567 shares. OncoSec Medical has a 12 month low of $0.88 and a 12 month high of $2.08. The firm’s market cap is $21.14 million. The company’s 50-day moving average is $0.99 and its 200 day moving average is $1.07.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/10/11/oncosec-medical-incorporated-oncs-given-buy-rating-at-maxim-group.html.

A number of institutional investors and hedge funds have recently made changes to their positions in ONCS. Gierl Augustine Investment Management purchased a new stake in OncoSec Medical in the fourth quarter worth about $0. Renaissance Technologies LLC purchased a new stake in shares of OncoSec Medical during the first quarter valued at approximately $111,000. Finally, Ridgeback Capital Investments L.P. purchased a new stake in shares of OncoSec Medical during the fourth quarter valued at approximately $3,063,000. Institutional investors and hedge funds own 8.98% of the company’s stock.

About OncoSec Medical

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.

Analyst Recommendations for OncoSec Medical (NASDAQ:ONCS)

Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.